A detailed history of Cwm, LLC transactions in Nektar Therapeutics stock. As of the latest transaction made, Cwm, LLC holds 3,355 shares of NKTR stock, worth $3,120. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,355
Holding current value
$3,120
% of portfolio
0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 08, 2024

BUY
$1.11 - $1.48 $3,724 - $4,965
3,355 New
3,355 $4,000
Q1 2023

Apr 28, 2023

SELL
$0.64 - $3.15 $376 - $1,855
-589 Reduced 70.2%
250 $0
Q4 2022

Feb 01, 2023

SELL
$2.03 - $4.28 $8,810 - $18,575
-4,340 Reduced 83.8%
839 $2,000
Q3 2022

Oct 27, 2022

BUY
$3.04 - $5.14 $15,309 - $25,885
5,036 Added 3521.68%
5,179 $17,000
Q2 2022

Jul 28, 2022

SELL
$3.17 - $6.17 $7,848 - $15,276
-2,476 Reduced 94.54%
143 $1,000
Q1 2022

Apr 21, 2022

BUY
$4.16 - $13.72 $9,830 - $32,420
2,363 Added 923.05%
2,619 $14,000
Q4 2021

Jan 31, 2022

BUY
$10.83 - $18.41 $1,689 - $2,871
156 Added 156.0%
256 $3,000
Q4 2020

Sep 15, 2021

SELL
$15.77 - $19.03 $63 - $76
-4 Reduced 3.85%
100 $2,000
Q4 2020

Jan 27, 2021

BUY
$15.77 - $19.03 $63 - $76
4 Added 4.0%
104 $2,000
Q3 2020

Sep 15, 2021

SELL
$16.59 - $24.79 $66 - $99
-4 Reduced 3.85%
100 $2,000
Q3 2020

Oct 19, 2020

BUY
$16.59 - $24.79 $66 - $99
4 Added 4.0%
104 $2,000
Q4 2019

Sep 14, 2021

SELL
$15.87 - $23.12 $920 - $1,340
-58 Reduced 36.71%
100 $2,000
Q4 2019

Jan 27, 2020

BUY
$15.87 - $23.12 $920 - $1,340
58 Added 58.0%
158 $3,000
Q1 2019

Apr 22, 2019

BUY
$31.58 - $46.35 $1,957 - $2,873
62 Added 163.16%
100 $3,000
Q4 2018

Jan 25, 2019

BUY
$30.43 - $56.65 $1,156 - $2,152
38 New
38 $1,000

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $174M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Cwm, LLC Portfolio

Follow Cwm, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cwm, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cwm, LLC with notifications on news.